LAKE FOREST, Calif.--(BUSINESS WIRE)--Sept. 29, 2004--

I-Flow To Be Awarded Deloitte Technology's Fast 50 Recognition During October 4th Awards Ceremony

I-Flow Corporation (NASDAQ: IFLO) today announced that it will be named to Deloitte's prestigious Technology Fast 50 Program for Orange County, a ranking of the 50 fastest growing technology and medical technology companies in the area by Deloitte & Touche, LLP, one of the country's leading professional services firms. Scheduled to be announced on October 4, 2004, Technology Fast 50 rankings are based on the percentage of growth in fiscal year revenues over five years--from 1999 to 2003.

"We are very pleased to be named to the Deloitte Technology Fast 50 Program again as this honor highlights our incredible growth over the past five years," said Donald M. Earhart, president and CEO of I-Flow Corporation. "It is clear that our strong clinical data combined with our growing sales force and an aggressive marketing effort is helping the company gain critical physician acceptance for our flagship ON-Q(R) brand, resulting in significant revenue growth," Earhart concluded.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 1999 and $1,000,000 in 2003, must be public or private companies headquartered in North America, and be a "technology company", defined as owning proprietary technology that contributes to a significant portion of the company's operating revenues (using other companies' technology in a unique way does not qualify); and/or devoting a significant proportion of revenues to research and development of technology.

"To make the Deloitte Technology Fast 50 (or the Technology Fast 50 Rising Star category), companies within Orange County must have had tremendous revenue growth from 1999-2003 (or 2001-2003 for Rising Stars). Deloitte applauds I-Flow Corporation for having the long-term vision to develop medical technologies that change the way we live," said Mark Miskinis, Deloitte partner, Technology, Media & Telecommunications practice, Costa Mesa.

Winners of the 19 regional Technology Fast 50 programs in the United States and Canada are automatically entered in the Deloitte Technology Fast 500 program, which ranks North America's top 500 fastest growing technology companies. For more information on the Deloitte Fast 50 or Fast 500 programs, visit www.fast500.com.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu," or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.

Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu. In the U.S., services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Tax LLP, and their subsidiaries), and not by Deloitte & Touche USA LLP.

About I-Flow Corporation

I-Flow Corporation (iflo.com) designs, develops and markets technically advanced, low-cost drug delivery systems and services that are redefining the standard of care by providing life-enhancing, cost-effective solutions for pain relief.

Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes," "anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release which seek to advise interested parties of the risks and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q, and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food Drug and Cosmetics Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes and product availability and acceptance. All such forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

    CONTACT: Schwartz Communications
             Wendy Williams or Julie Normart, 781-684-0770
             iflo@schwartz-pr.com
             or
             I-Flow Corporation
             Orlando Rodrigues, 949-206-2619
             orlandorodrigues@iflo.com

    SOURCE: I-Flow Corporation